Aortic Stenosis Clinical Trial
— TCWOfficial title:
TransCatheter Aortic Valve Implantation and Fractional Flow Reserve-Guided Percutaneous Coronary Intervention Versus Conventional Surgical Aortic Valve Replacement and Coronary By-Pass Grafts for Treatment of Patients With Coronary MultiVessel Disease and Aortic Valve Stenosis
Verified date | January 2024 |
Source | Maatschap Cardiologie Zwolle |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The trial objective is to investigate whether Fractional Flow Reserve (FFR)-Guided Percutaneous Coronary Intervention (PCI) and TransCatheter Aortic Valve Implantation (TAVI) strategy for treatment of multivessel disease and aortic stenosis will be non-inferior to Coronary Artery By-pass Grafting (CABG) and Surgical Aortic Valve Replacement (SAVR) for a composite primary endpoint of all-cause mortality, stroke, myocardial infarction, coronary or valve re-intervention and life-threatening or disabling bleeding at one year.
Status | Active, not recruiting |
Enrollment | 172 |
Est. completion date | November 1, 2024 |
Est. primary completion date | April 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 70 Years and older |
Eligibility | Inclusion Criteria: 1. Symptomatic patients aged =70 years with aortic stenosis fulfilling one of these criteria (Aortic Valve Area (AVA) =1 cm2; mean gradient =40 mmHg; Aortic jet velocity >4 m/sec; or Velocity index = 0.25) feasible for treatment by both trans femoral or subclavian approach TAVI as well as conventional SAVR and where the Heart Team decides that treatment is needed (final decision is left to the Heart Team) 2. Presence of =2 de novo coronary lesions of =50% diameter stenosis on visual estimation located in any of main epicardial coronary arteries, or side branches of a lumen caliber of more than 2 mm or single Left Anterior Descending (LAD) lesion with more than 20 mm length or involving a bifurcation (complex), feasible for treatment with CABG as well as PCI (Heart Team decision) 3. Patients willing and capable to provide written informed consent Exclusion Criteria: 1. Patients in cardiogenic shock or acute heart failure, requiring inotropic agents during procedure and/or i.v. diuretics <48 hours before procedure 2. Left ventricular ejection fraction <30% 3. Concomitant presence of other than aortic valve disease requiring intervention 4. Previous CABG, SAVR, TAVI or thoracotomy for any other reason 5. Bicuspid or unicuspid aortic valve 6. Recent myocardial infarction (less than 2 weeks) 7. Involvement of left main trifurcation (all three branches being larger than 2 mm) 8. Expected total stent length more 60mm per vessel 9. FFR measurement judged impossible 10. Life expectancy <1 year 11. Known malignancy 12. Contraindication for dual antiplatelet therapy or expected surgical intervention requiring interruption of Dual Antiplatelet Therapy (DAPT) in the first 6 months 13. Reduced renal function (Glomerular Filtration Rate (GFR) <29 ml/min/1.73m2; Kidney Disease Outcomes Quality Initiative (KDOQI) stage 4 and 5) 14. Previous disabling stroke, Transient Ischemic Attack (TIA) in the last 6 months, or known severe stenosis of carotid or vertebral arteries 15. Participation in other investigational clinical trials |
Country | Name | City | State |
---|---|---|---|
Austria | Medical University of Graz | Graz | |
Austria | General Hospital Vienna | Vienna | |
Denmark | Rigshospitalet, Copenhagen University Hospital | Copenhagen | |
France | CHU de Bordeaux | Bordeaux | |
France | CHRU de Lille | Lille | |
France | Clinique Pasteur | Toulouse | |
Germany | Universitäres Herz- und Gefäßzentrum UKE Hamburg GmbH | Hamburg | |
Greece | Onassis Cardiac Surgery Center | Kallithéa | |
Netherlands | OLVG | Amsterdam | |
Netherlands | Hagaziekenhuis | Den Haag | |
Netherlands | UMCG | Groningen | |
Netherlands | St. Antonius hospital | Nieuwegein | |
Netherlands | Radboudumc | Nijmegen | |
Netherlands | HagaZiekenhuis | The Hague | |
Netherlands | Isala hospital | Zwolle | |
Poland | Medical University of Silesia | Katowice | |
Poland | University hospital Opole | Opole | |
Portugal | Hospital de Santa Cruz | Lisboa | |
Slovakia | SUSCCH | Banská Bystrica | |
Spain | Hospital Clinico Universitario San Carlos | Madrid | |
Spain | Hospital Clínico Valladolid | Valladolid |
Lead Sponsor | Collaborator |
---|---|
Maatschap Cardiologie Zwolle | Medtronic |
Austria, Denmark, France, Germany, Greece, Netherlands, Poland, Portugal, Slovakia, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary endpoint is a composite of all-cause mortality, myocardial infarction, disabling stroke, unscheduled clinically-driven target vessel revascularization, valve re-intervention, and life threatening or disabling bleeding at one year | one year | ||
Secondary | Major Adverse Cardiac Events (MACE: a composite of cardiovascular mortality, all stroke, myocardial infarction, unscheduled coronary or valve re-intervention) at one year | one year | ||
Secondary | All-cause mortality and all stroke at 30 days and at one year | 30 days and one year | ||
Secondary | Life-threatening or disabling bleeding at 30 days and one year | 30 days and one year | ||
Secondary | Life-threatening or disabling bleeding and major bleeding at 30 days and at one year | 30 days and one year | ||
Secondary | Rate of conduction disturbances requiring a permanent pacemaker at 30 days and at one year | 30 days and one year | ||
Secondary | Access-related complications at 30 days | 30 days | ||
Secondary | Acute kidney injury (Acute Kidney Injury Network (AKIN) classification) at 30 days and at one year | 30 days and one year | ||
Secondary | Stent thrombosis according to Academic Research Consortium (ARC) criteria (definite and probable) at 30 days and at one year | 30 days and one year | ||
Secondary | Device success (Valve Academic Research Consortium (VARC) 2 definition) | procedure | ||
Secondary | Early Safety at 30 days (VARC 2 definition) | 30 days | ||
Secondary | Early Efficacy at 30 days (VARC 2 definition) | 30 days | ||
Secondary | Time Related Valve Safety at 30 days (VARC 2 definition) | 30 days | ||
Secondary | Echocardiographic assessment of prosthetic valve performance at discharge and at one year using the following measures: a) transvalvular mean gradient, b) Effective Orifice Area (EOA), c) degree of prosthetic aortic valve regurgitation | discharge and at one year | ||
Secondary | Clinically driven revascularisation at 30 days and at one year | 30 days and one year | ||
Secondary | Change in New York Heart Association (NYHA) class before treatment, at 30 days and at one year | 30 days and one year | ||
Secondary | Change in Canadian Cardiovascular Society (CCS) class before treatment, at 30 days and at one year | 30 days and one year | ||
Secondary | Quality of life (Short Form (SF)-36) before treatment and at one year | one year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04310046 -
Optimal Timing of Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention - The TAVI PCI Trial
|
N/A | |
Completed |
NCT03332745 -
Mechanism of Decompensation Evaluation - Aortic Stenosis
|
||
Recruiting |
NCT06008080 -
Post-Market Clinical Follow Up Study With Navitor Valve
|
||
Recruiting |
NCT06055751 -
Long Term Evaluation of Cardiac Arrhythmias After Transcatheter Aortic Valve Implantation -The LOCATE Registry
|
||
Active, not recruiting |
NCT04815785 -
Safety and Efficacy of TaurusOne® Transcatheter Aortic Valve System in Patients With Severe Calcific Aortic Stenosis
|
N/A | |
Terminated |
NCT02202434 -
Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement
|
N/A | |
Recruiting |
NCT03029026 -
The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.
|
||
Active, not recruiting |
NCT02903420 -
A Clinical Trial of Transcatheter Aortic Valves in Dialysis Patients (Japan)
|
N/A | |
Completed |
NCT02629328 -
CardioCel Tri-leaflet Repair Study
|
N/A | |
Completed |
NCT02306226 -
Symetis ACURATE Neo™ Valve Implantation SAVI TF Registry
|
||
Withdrawn |
NCT01648309 -
Neuropsychological Testing in Patients Undergoing Transvascular Aortic Valve Implantation
|
N/A | |
Completed |
NCT01676727 -
ADVANCE Direct Aortic Study
|
||
Completed |
NCT01422044 -
Risk Prediction in Aortic Stenosis
|
N/A | |
Withdrawn |
NCT00774657 -
Ventricular Remodeling In Patients With Aortic Stenosis Assessed Echocardiography
|
N/A | |
Terminated |
NCT00535899 -
Speckle Tracking Imaging in Patients With Low Ejection Fraction Aortic Stenosis (SPArKLE-AS)
|
N/A | |
Terminated |
NCT05070130 -
OpSens PRIME CLASS
|
||
Completed |
NCT03314857 -
China XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population
|
N/A | |
Completed |
NCT04157920 -
Impact of Predilatation Between Self-expanding Valves
|
N/A | |
Enrolling by invitation |
NCT06212050 -
Feasibility, Safety, and Effectiveness of the ACURATE neo2 Transcatheter Heart Valve for Severe Bicuspid Aortic Stenosis
|
||
Recruiting |
NCT05893082 -
Multicenter Feasibility Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
|
N/A |